Type 2 Diabetes Mechanisms Split by BMI in African Adults, Mismatching Standard Treatments

Amsterdam UMC and University of Ghana researchers stratified patients by BMI and measured insulin dynamics, retinopathy, stroke, hypertension and kidney disease. Lean participants exhibited more retinopathy and strokes linked to early-life malnutrition impairing pancreatic development; overweight participants showed elevated hypertension and cardiovascular risk tied to adiposity-driven resistance.

UK Biobank data confirm Africans develop diabetes at lower BMI thresholds than Europeans, yet international guidelines apply metformin and sulfonylureas uniformly. These agents primarily address resistance, leaving lean patients potentially undertreated and contributing to documented poorer glycemic control in African-descent populations in Europe.

The insulin-resistance subgroup may benefit from adjunctive microbiome modulation via targeted probiotics that improve glucose uptake, but no such benefit is expected in primary insulin-deficiency cases. Phenotype-specific trials are required to quantify differential responses.

Next, RCTs must enroll lean versus overweight African cohorts, test insulin secretagogues or replacement against resistance-focused regimens, and track microvascular endpoints over 24 months.